Sign in

What researchers published on Burkitt lymphoma

1,933 papers, newest first.

Showing 20 of 31

  • Trial resultNovel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.Blood advances
  • Randomised trialRituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.European journal of haematology
  • Randomised trialR-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.The Lancet. Haematology
  • Trial resultNext-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.Blood cancer journal
  • Trial resultBlinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.American journal of hematology
  • Trial resultCD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.Blood
  • Trial resultA novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia.American journal of hematology
  • Trial resultBlinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.Pediatric blood & cancer
  • Trial resultPreferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.Blood advances
  • Trial resultEfficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.Blood
  • Trial resultSequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.Blood advances
  • Trial resultIKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial.Blood advances
  • Trial resultCAR19/22 T cell therapy in adult refractory Burkitt's lymphoma.Cancer immunology, immunotherapy : CII
  • Trial resultA dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.British journal of haematology
  • Trial resultFavourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.Annals of oncology : official journal of the European Society for Medical Oncology
  • Trial resultMean platelet counts are relatively decreased with malaria but relatively increased with endemic Burkitt Lymphoma in Uganda, Tanzania, and Kenya.British journal of haematology
  • Trial resultRituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4.Pediatric hematology and oncology
  • Trial resultClinicopathologic Characterization of Children With B-Cell Non-Hodgkin Lymphoma Over 10 Years at a Tertiary Center in Cape Town, South Africa.Journal of pediatric hematology/oncology
  • Trial resultEarly response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.Blood
  • Trial resultExperience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.British journal of haematology